InfanDx AG

InfanDx develops diagnostic system for perinatal asphyxia (oxygen deficit during birth) and its most relevant outcome, brain damage. The company's primary focus is the early identification of newborns suffering from critical oxygen supply deficit during birth (Asphyxia), a major cause for brain injury often followed by life long disabilitation.

InfanDx develops diagnostic system for perinatal asphyxia (oxygen deficit during birth) and its most relevant outcome, brain damage. The company's primary focus is the early identification of newborns suffering from critical oxygen supply deficit during birth (Asphyxia), a major cause for brain injury often followed by life long disability.

Sector:
- Biotechnology / R&D Services

Subsectors:
- Diagnostic instrumentation

Primary therapeutic areas:
- Diseases of the nervous system

Business model:
- R&D

Customer segments:
- Hospitals
- Large biotech & big pharma

Kontakt

InfanDx AG
BioCampus Cologne
Nattermannallee 1
50829 Köln - Germany
Tel: +49 (0) 221 3008 9783
ron.meyer(at)infandx.com
www.infandx.com